$72.70 +0.50 (%) Novartis Shs Sponsored American Deposit Receipt Repr 1 Sh - NYSE

Feb. 12, 2016 | 04:00 PM

Partner Headlines

  1. Valeant's Share Price Continues to Decline

    GuruFocus | Feb. 5, 2016 | 15:10PM EST
  2. Earnings Recap For January 27

    Benzinga | Jan. 27, 2016 | 17:17PM EST
  3. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus | Jan. 26, 2016 | 14:59PM EST
  4. Guru Stocks at 52-Week Lows

    GuruFocus | Jan. 26, 2016 | 12:26PM EST
  5. Juno Buyout Puts Single-Cell Sequencing In Spotlight

    IBD | Jan. 15, 2016 | 17:30PM EST
  6. Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows

    GuruFocus | Jan. 11, 2016 | 13:36PM EST
  7. Novartis Announces Collaboration and Licensing Agreement with Surface Oncology

    Benzinga | Jan. 11, 2016 | 04:19AM EST
  8. Mylan, Momenta Team Up To Develop Biosimilar Drugs

    IBD | Jan. 8, 2016 | 15:34PM EST
  9. 3 Potential Blockbuster Drugs Launching in 2016

    IBD | Jan. 6, 2016 | 09:42AM EST
  10. Berkshire Hathaway, China Mobile, Novartis, Oracle, PetroChina Near 52-Week Lows

    GuruFocus | Jan. 4, 2016 | 12:52PM EST
  11. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD | Dec. 17, 2015 | 17:08PM EST
  12. Novartis Announces New CTL019 Study Data Demonstrating Overall Response in Adults with Certain Types of Lymphoma at #ASH2015

    Benzinga | Dec. 6, 2015 | 08:43AM EST
  13. Novartis Announces Phase III Studies of Jakavi Show Disease Improvement in Patients with Myelofibrosis and Polycythemia Vera

    Benzinga | Dec. 5, 2015 | 10:18AM EST
  14. Weekend Watch: Yahoo's Fate, Blood Cancer Fighters

    IBD | Dec. 5, 2015 | 08:02AM EST
  15. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD | Dec. 4, 2015 | 13:46PM EST
  16. Blood-Cancer Drugs In Focus

    IBD | Dec. 2, 2015 | 18:47PM EST
  17. Blood-Cancer Fighters To Strut Their Stuff At ASH

    IBD | Dec. 2, 2015 | 08:02AM EST
  18. Sanofi Chipping Away At Biogen's MS Dominance

    IBD | Nov. 30, 2015 | 11:32AM EST
  19. Skin Disease Drug Costs Jump

    IBD | Nov. 25, 2015 | 18:34PM EST
  20. Biotechs Weaken, But These Names Have Bullish Charts

    IBD | Nov. 25, 2015 | 17:19PM EST
  21. Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

    IBD | Nov. 25, 2015 | 17:01PM EST
  22. Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis

    Benzinga | Nov. 23, 2015 | 04:12AM EST
  23. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD | Nov. 18, 2015 | 15:36PM EST
  24. Novartis Presents New Two-year Data for Cosentyx Showing No Progression in Joint Damage in 84% of Psoriatic Arthritis Patients

    Benzinga | Nov. 7, 2015 | 20:03PM EST
  25. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD | Nov. 5, 2015 | 17:37PM EST
  26. Roche Touts New MS Drug As Legacy Players Hit Snags

    IBD | Nov. 3, 2015 | 08:02AM EST
  27. Guru Stocks at 52-Week Lows: NVS, WMT, IBM, AXP, CHU

    GuruFocus | Nov. 1, 2015 | 17:27PM EST
  28. AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance

    IBD | Oct. 30, 2015 | 10:00AM EST
  29. Apple Upgraded, Alibaba PTs Hiked, Twitter PTs Cut

    IBD | Oct. 28, 2015 | 09:39AM EST
  30. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD | Oct. 22, 2015 | 12:36PM EST
  31. Novartis, Google Developing Smart Lenses

    FoxBusiness | Oct. 21, 2015 | 11:09AM EST
  32. Elbit Imaging Announces Novartis to Invest $5M in Gamida for ~2.5% Stake

    Benzinga | Oct. 12, 2015 | 10:35AM EST
  33. Novartis Division Alcon Receives FDA Approval for AcrySof®IQ Aspheric IOL with UltraSert Pre-loaded Delivery System

    Benzinga | Oct. 5, 2015 | 04:14AM EST
  34. US Stock Futures Up; All Eyes On Jobs Report

    Benzinga | Oct. 2, 2015 | 07:37AM EST
  35. FDA Accepts Novartis/Sandoz Regulatory Submission for Proposed Biosimilar to Enbrel

    Benzinga | Oct. 2, 2015 | 04:19AM EST
  36. Novartis Announces NEJM Publication Of Secukinumab Phase III Data Confirming Significant Efficacy In Patients With Psoriatic Arthritis

    Benzinga | Sep. 30, 2015 | 17:02PM EST
  37. Bristol-Myers, J&J Upgraded On New Drug Prospects

    IBD | Sep. 29, 2015 | 15:00PM EST
  38. Roche Drug Scores A Hit Against Stubborn Form Of MS

    IBD | Sep. 28, 2015 | 11:48AM EST
  39. Novartis Reports Patients with Aggressive Form of Melanoma Lived Average of Two+ Years When Taking Tafinlar + Mekinist

    Benzinga | Sep. 27, 2015 | 18:23PM EST
  40. Novartis' Afinito Significantly Improves Progression-Free Survival In Advanced Nonfunctional GI and Lung NET

    Benzinga | Sep. 27, 2015 | 06:48AM EST
  41. Novartis' New Heart Failure Medicine Entresto Receives CHMP Recommendation for EU Approval

    Benzinga | Sep. 25, 2015 | 04:31AM EST
  42. US Stock Futures Tumble; Jobs Report In Focus

    Benzinga | Sep. 4, 2015 | 07:09AM EST
  43. Novartis Announces EU approval for Farydak

    Benzinga | Sep. 4, 2015 | 04:45AM EST
  44. Swiss Miss: Switzerland Skirts Recession, But ETFs Struggle

    Benzinga | Aug. 28, 2015 | 14:32PM EST
  45. US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

    Benzinga | Aug. 21, 2015 | 07:06AM EST
  46. Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop Treatments for MS, Other Autoimmune Indications

    Benzinga | Aug. 21, 2015 | 04:34AM EST
  47. Valeant Pharmaceuticals' New Female Drug

    GuruFocus | Aug. 20, 2015 | 12:47PM EST
  48. Benzinga's Top #PreMarket Gainers

    Benzinga | Aug. 17, 2015 | 08:08AM EST
  49. AVEO Announces Exclusive Worldwide License Agreement for, Development, Commercialization of AV-380 and Related Antibodies

    Benzinga | Aug. 17, 2015 | 06:02AM EST
  50. Benzinga's Top #PreMarket Gainers

    Benzinga | Aug. 14, 2015 | 08:17AM EST
Trading Center